Renew Your Membership

Deepak L. Bhatt, MD, MPH, MBA, FACC

Deepak L. Bhatt, MD, MPH, FACC

Professional Bio:

Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, is the Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York City. After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his science degree as a National Merit Scholar at MIT, his MD from Cornell, an MPH from Harvard, and an Executive MBA from Oxford. He trained in internal medicine at the University of Pennsylvania and in cardiology at Cleveland Clinic. He completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent many years as an interventional cardiologist, Associate Professor of Medicine, Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He then served as the Chief of Cardiology at VA Boston Healthcare System and subsequently as Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital. He was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. He became a full Professor of Medicine at Harvard Medical School in 2012. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He received the Research Mentor Award from Brigham and Women’s Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s in 2017, ACC’s Distinguished Mentor Award in 2018, AHA’s Distinguished Scientist Award in 2019, NLA’s Honorary Lifetime Membership Award in 2021, and SCAI’s Master designation in 2022. Dr. Bhatt has authored or co-authored over 2000 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2023. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-Editors of Braunwald’s Heart Disease. He had served as Senior Associate Editor for News and Clinical Trials for and is the Editor of the Journal of Invasive Cardiology. He was the PI for CHARISMA, CRESCENDO, COGENT, REDUCE-IT, SOLOIST, SCORED, and ENTRIGUE and co-PI of the three CHAMPION trials, STAMPEDE, SAVOR-TIMI 53, SYMPLICITY HTN-3, THEMIS, THEMIS-PCI, and the REACH registry. In 2014, he was listed in the AHA/ASA top advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3); in 2018, REDUCE-IT was listed and also named the top cardiology trial by NEJM; in 2020 and again in 2021, SOLOIST and SCORED were listed by the AHA. He was the inaugural Chair of the AHA-GWTG Quality Oversight Committee and served as a Trustee of the ACC, and currently serves on the Board of Directors of the AHA New York City chapter.

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Elsevier Practice Update Cardiology(SIGNIFICANT), Medtelligence/WebMD(SIGNIFICANT), WebMD(SIGNIFICANT), Level Ex(SIGNIFICANT), K2P(SIGNIFICANT), MJH Life Sciences(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Piper Sandler(MODEST), Arnold and Porter law firm(SIGNIFICANT), Cowen and Company(MODEST), Wiley(SIGNIFICANT), Oakstone CME(SIGNIFICANT), Broadview Ventures(SIGNIFICANT), McKinsey(SIGNIFICANT), Hims(SIGNIFICANT), CSL Behring (SIGNIFICANT), Youngene(SIGNIFICANT), SFJ(SIGNIFICANT), GlaxoSmithKline(MODEST) EQUITY INTERESTS/STOCK OPTIONS: DRS.LINQ(SIGNIFICANT), AngioWave(SIGNIFICANT), High Enroll(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT) OFFICER, DIRECTOR ETC: TobeSoft(SIGNIFICANT), DRS.LINQ(SIGNIFICANT), AngioWave(SIGNIFICANT), High Enroll(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Eisai(SIGNIFICANT), FlowCo(NONE), Roche(SIGNIFICANT), Sanofi Aventis(SIGNIFICANT), Bristol Myers Squibb(SIGNIFICANT), Takeda(NONE), Pfizer Inc(SIGNIFICANT), Forest Laboratories(SIGNIFICANT), Amarin(SIGNIFICANT), Astra Zeneca(SIGNIFICANT), Medtronic(SIGNIFICANT), Ethicon(SIGNIFICANT), Ischemix(SIGNIFICANT), The Medicines Company(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Chiesi(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Ironwood(SIGNIFICANT), Abbott(SIGNIFICANT), Regeneron(SIGNIFICANT), PhaseBio(SIGNIFICANT), Idorsia(SIGNIFICANT), Synaptic(SIGNIFICANT), Afimmune(SIGNIFICANT), Fractyl(SIGNIFICANT), PLx Pharma(SIGNIFICANT), Lexicon(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Cardax(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), MyoKardia(SIGNIFICANT), Owkin(SIGNIFICANT), HLS Therapeutics(SIGNIFICANT), 89Bio(SIGNIFICANT), Garmin(SIGNIFICANT), Novartis(SIGNIFICANT), NirvaMed(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT), Stasys(SIGNIFICANT), Faraday(SIGNIFICANT), Aker Biomarine(SIGNIFICANT), Recardio(SIGNIFICANT), Beren(SIGNIFICANT), Moderna(SIGNIFICANT), CinCor(SIGNIFICANT), Youngene(SIGNIFICANT), Cleerly(SIGNIFICANT), Otsuka(SIGNIFICANT), Alnylam(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Merck & Co., Inc.(NONE), Journal of Invasive Cardiology(SIGNIFICANT), Belvoir Publications(SIGNIFICANT), Clinical Cardiology(NONE), Slack Publications/Cardiology Research Foundation(SIGNIFICANT), HMP Global(SIGNIFICANT), Janssen Pharmaceuticals, Inc(MODEST), Novo Nordisk Inc.(MODEST), MyoKardia(SIGNIFICANT), CellProthera(SIGNIFICANT), Cereno Scientific(SIGNIFICANT), Cardax(SIGNIFICANT), PLx Pharma(SIGNIFICANT), Elsevier(SIGNIFICANT), PhaseBio(SIGNIFICANT), NirvaMed(SIGNIFICANT), Medscape Cardiology(NONE), Regado Biosciences(NONE), Stasys(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Merck(MODEST), Lexicon(NONE)

View Full Disclosure